These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20071185)

  • 1. Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens.
    Morioka M; Kamizono A; Takikawa H; Mori A; Ueno H; Kadowaki S; Nakao Y; Kato K; Umezawa K
    Bioorg Med Chem; 2010 Feb; 18(3):1143-8. PubMed ID: 20071185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens.
    Labaree DC; Zhang JX; Harris HA; O'Connor C; Reynolds TY; Hochberg RB
    J Med Chem; 2003 May; 46(10):1886-904. PubMed ID: 12723952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent.
    Neale JR; Richter NB; Merten KE; Taylor KG; Singh S; Waite LC; Emery NK; Smith NB; Cai J; Pierce WM
    Bioorg Med Chem Lett; 2009 Feb; 19(3):680-3. PubMed ID: 19117754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats.
    Bauss F; Esswein A; Reiff K; Sponer G; Müller-Beckmann B
    Calcif Tissue Int; 1996 Sep; 59(3):168-73. PubMed ID: 8694893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term sensitivity of uterus and hypothalamus/pituitary axis to 17beta-estradiol is higher than that of bone in rats.
    Erben RG; Brunner KS; Breig B
    J Bone Miner Res; 2004 Nov; 19(11):1827-32. PubMed ID: 15476583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes modulates differentially creatine kinase-specific activity responsiveness to estradiol-17beta and to raloxifene in rat organs.
    Somjen D; Shen M; Stern N; Mirsky N
    J Cell Biochem; 2006 Sep; 99(1):133-9. PubMed ID: 16598752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate sequestering agents. Synthesis and preliminary evaluation for in vitro and in vivo uranium(VI) chelation.
    Sawicki M; Lecerclé D; Grillon G; Le Gall B; Sérandour AL; Poncy JL; Bailly T; Burgada R; Lecouvey M; Challeix V; Leydier A; Pellet-Rostaing S; Ansoborlo E; Taran F
    Eur J Med Chem; 2008 Dec; 43(12):2768-77. PubMed ID: 18313802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
    Feher A; Koivunemi A; Koivunemi M; Fuchs RK; Burr DB; Phipps RJ; Reinwald S; Allen MR
    Bone; 2010 Jan; 46(1):203-7. PubMed ID: 19857619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effect of soy protein, soy isoflavones, and 17beta-estradiol on bone metabolism in adult ovariectomized rats.
    Cai DJ; Zhao Y; Glasier J; Cullen D; Barnes S; Turner CH; Wastney M; Weaver CM
    J Bone Miner Res; 2005 May; 20(5):828-39. PubMed ID: 15824856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
    Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The estrogenic activities of 2-[3-estrone-N-ethyl-piperazine-methyl]tetracycline(XW630)--a new compound with anti-osteoporosis activity].
    Mo Z; Jiao X; Su H; Zheng H; Weng L
    Yao Xue Xue Bao; 1998 Sep; 33(9):645-9. PubMed ID: 12016866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice.
    Onoe Y; Miyaura C; Ito M; Ohta H; Nozawa S; Suda T
    J Bone Miner Res; 2000 Mar; 15(3):541-9. PubMed ID: 10750569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue distribution and pharmacological potential of SM-16896, a novel oestrogen-bisphosphonate hybrid compound.
    Tsushima N; Yabuki M; Harada H; Katsumata T; Kanamaru H; Nakatsuka I; Yamamoto M; Nakatsuka M
    J Pharm Pharmacol; 2000 Jan; 52(1):27-37. PubMed ID: 10716600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that ibuprofen antagonizes selective actions of estrogen and tamoxifen on rat bone.
    Sibonga JD; Bell NH; Turner RT
    J Bone Miner Res; 1998 May; 13(5):863-70. PubMed ID: 9610751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of estradiol-17beta, testosterone and a black cohosh preparation on bone and prostate in orchidectomized rats.
    Seidlová-Wuttke D; Jarry H; Pitzel L; Wuttke W
    Maturitas; 2005 Jun; 51(2):177-86. PubMed ID: 15917159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats.
    Bowman AR; Sass DA; Marshall I; Ma YF; Liang H; Jee WS; Epstein S
    J Bone Miner Res; 1996 Aug; 11(8):1191-8. PubMed ID: 8854256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
    Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
    Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
    Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
    J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Synthesis and antiosteoporosis activity of steroid-bisphosphonate compounds].
    Zheng H; Wu Y; Chen J; Weng L
    Yao Xue Xue Bao; 1998 May; 33(5):339-43. PubMed ID: 12017000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat.
    Müller K; Wiesenberg I; Jaeggi K; Green JR
    Arzneimittelforschung; 1998 Jan; 48(1):81-6. PubMed ID: 9522039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.